China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics
- Written by ACN Newswire
HONG KONG, Jun 28, 2021 - (ACN Newswire) - 2021-6-23 / Gelonghui - China Biotech's cell therapy was approved by the NMPA to enter Phase I clinical trials as a Class I new drug, while the recent CAR-T cell therapy approval for product marketing in China means a new era of immune cell therapy has begun.
According to...
| Source: official website of NMPA |
 |
 |
 |